Blogs | MedChemExpress

Opnurasib (JDQ-443) is an Orally Active KRAS G12C Inhibitor

Opnurasib (JDQ-443) is a structurally novel, potent, and selective covalent oral inhibitor of KRAS G12C that exhibits antitumor activity.
OTS193320 is a SUV39H2 Methyltransferase Activity Inhibitor

OTS193320 is a potent SUV39H2 methyltransferase activity inhibitor. OTS193320 triggers apoptotic cell death.
Adagrasib (MRTX849), a Potent KRAS G12C Inhibitor for KRAS G12C-mutated Locally Advanced or Metastatic NSCLC Research

Adagrasib (MRTX849) is an orally available, and mutation-selective covalent inhibitor of KRAS G12C. Can be used for NSCLC research.
A947 is a Selective and Efficacious SMARCA2 PROTAC in SMARCA4 Mutant Cancers

A947 is a selective SMARCA2 (PROTAC). A947 also is a moderately selective SMARCA2 degrader. A947 can be used for the research of cancer.
Mitonafide is a Cytostatic Agent, Inhibiting DNA and RNA Synthesis

Mitonafide, a potent cytostatic agent, can inhibit DNA and RNA synthesis. Mitonafide is a potent antitumor agent.
BI-0474 is a Potent KRAS G12C inhibitor

BI-0474 is a potent KRAS G12C inhibitor and exhibits good anti-proliferative activity against NCI-H358 cells carrying the G12C mutation.
BT5528 is a Bicyclic Peptide Toxin Conjugate, an EphA2 Activator.

BT5528 is a bicyclic peptide toxin conjugate, an EphA2 activator. BT5528 shows potent anti-tumor activity.
G12Si-5 is a K-Ras G12S Mutant Covalent Inhibitor

G12Si-5, a potent, selective and reversible covalent inhibitor of the K-Ras G12S, can be used for the research of cancer.
Tiragolumab is An Immune Checkpoint Inhibitor Binding to T-cell Immunoglobulin and TIGIT

Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
Seliciclib (Roscovitine) is an Orally Active and Selective CDKs Inhibitor

Seliciclib, a potent, selective and orally active CDKs inhibitor, preferentially inhibits CDK2, CDK7 and CDK9.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (63)